Roskoski R Jr - Search Results

1

Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2021 Mar 26;168:105579. doi: 10.1016/j.phrs.2021.105579. Online ahead of print. Pharmacol Res. 2021. PMID: 33774181 Review.

2

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26. Pharmacol Res. 2021. PMID: 33513356 Review.

3

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2021 Mar;165:105422. doi: 10.1016/j.phrs.2021.105422. Epub 2021 Jan 9. Pharmacol Res. 2021. PMID: 33434619 Review.

4

NIH funding trends to US medical schools from 2009 to 2018.

Noble P, Ten Eyck P, Roskoski R Jr, Jackson JB. Noble P, et al. Among authors: roskoski r jr. PLoS One. 2020 Jun 1;15(6):e0233367. doi: 10.1371/journal.pone.0233367. eCollection 2020. PLoS One. 2020. PMID: 32480400 Free PMC article.

5

The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 May;155:104725. doi: 10.1016/j.phrs.2020.104725. Epub 2020 Feb 25. Pharmacol Res. 2020. PMID: 32109580 Review.

6

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. Pharmacol Res. 2020. PMID: 31862477 Review.

7

The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23. Pharmacol Res. 2020. PMID: 31770593 Review.

8

Corrigendum to "Targeting ERK1/2 protein-serine/threonine kinases in human cancers" [Pharmcol. Res. 142 (2019) 151-168].

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 May;143:206. doi: 10.1016/j.phrs.2019.03.019. Epub 2019 Apr 3. Pharmacol Res. 2019. PMID: 30952557 No abstract available.

9

Properties of FDA-approved small molecule protein kinase inhibitors.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13. Pharmacol Res. 2019. PMID: 30877063 Review.

10

Targeting ERK1/2 protein-serine/threonine kinases in human cancers.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Apr;142:151-168. doi: 10.1016/j.phrs.2019.01.039. Epub 2019 Feb 20. Pharmacol Res. 2019. PMID: 30794926 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results